Clinical trial · Interventional
Universal Genetic Testing for Cancer Risk Reduction
NCT06926816CI-TRIAL-00104307recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to see if offering genetic testing for cancer-related genes is feasible and acceptable for patients presenting for gynecology clinic visits, instead of needing to see specialized providers or needing to meet specific criteria. The primary aim to assess the proportion of patients who undergo genetic testing, and the proportion of patients with pathogenic variants.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Genetic Testing | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Natera® Empower™ hereditary cancer panel test | Genetic | — | UNRESOLVED |
| Specialist Referral | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Completed genetic screening test
- description
- Participants will complete point-of-care genetic testing by saliva test. Participants with actionable pathogenic variants will be referred to the appropriate specialists to discuss risk-reduction strategies and offered genetic counseling. All Participants will be given the opportunity for genetic counseling, and if interested and desired this will be facilitated by the research team.
- interventionNames
- Genetic: Natera® Empower™ hereditary cancer panel test
- Other: Specialist Referral
- type
- NO_INTERVENTION
- label
- Denied genetic screening test
- description
- Participants in this arm have declined the genetic screening test.
Primary outcomes (1)
- measure
- Number of participants who undergo genetic testing
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
- Maximum age
- 39 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female patients between ages of 25-39 years at the time of visit 2. Receive gynecologic care at an affiliated NYU Langone Health (NYULH) site listed in this protocol. Exclusion Criteria: 1. Personal history of ovarian, fallopian tube, primary peritoneal, or uterine cancers 2. Previously undergone germline testing for ovarian cancer risk variants (prior commercial saliva-based kits, such as 23andMe, are acceptable) 3. History of bilateral salpingo-oophorectomy 4. Visit related to pregnancy or immediately postpartum (within 2 weeks)
References
Publications (0)
Data not yet available
No reference posted for this study.